Evidence map›Paper›PMID 39192651›Full record

ArticleCurrent medicinal chemistry2025

The Investigation of Nfκb Inhibitors to Block Cell Proliferation in OSCC Cells Lines.

Yuxi Cheng, Liping Wang, Shuju Zhang, Wei Jian, Bin Zeng, Long Liang, Zhiyuan Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Natural flavonoid isoorientin and its anticancer mechanisms: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuxi ChengHunan Key Laboratory of Oral Health Research & Hunan 3D Printing Engineering Research Center of Oral Care & Hunan Clinical Research Center of Oral Major Diseases and Oral Health & Academician Workstation for Oral-maxilofacial and Regenerative Medicine & Xiangya Stomatological Hospital & Xiangya School of Stomatology, Central South University, Xiangya Road, Changsha, 410011, China.
Liping WangHunan Key Laboratory of Oral Health Research & Hunan 3D Printing Engineering Research Center of Oral Care & Hunan Clinical Research Center of Oral Major Diseases and Oral Health & Academician Workstation for Oral-maxilofacial and Regenerative Medicine & Xiangya Stomatological Hospital & Xiangya School of Stomatology, Central South University, Xiangya Road, Changsha, 410011, China.
Shuju ZhangHunan Children's Hospital, Changsha, 410011, China.
Wei JianDental Department, Yueyang Central Hospital, 39# Dongmaoling Road, Yueyang, 414000, China.
Bin ZengDepartment of Stomatology, Changsha Medical University, Changsha, Hunan, 410219, China.
Long LiangHunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences , Molecular Biology Research Center, 110# Xiangya Road, Changsha, 410011, China.
Zhiyuan DengHunan Key Laboratory of Oral Health Research & Hunan 3D Printing Engineering Research Center of Oral Care & Hunan Clinical Research Center of Oral Major Diseases and Oral Health & Academician Workstation for Oral-maxilofacial and Regenerative Medicine & Xiangya Stomatological Hospital & Xiangya School of Stomatology, Central South University, Xiangya Road, Changsha, 410011, China.

Funding

Changsha Municipal Natural Science Foundation kq2014216National Natural Science Foundation of China 82201081Natural Science Foundation of Hunan Province 2021JJ40901Research Foundation for Young Teachers of Xiangya Stomatology Hospital 2020YQ02
6 · The paper itself

Abstract

backgroundOral cancers, with oral squamous cell carcinoma (OSCC) as the predominant type, have a significant impact on morbidity and mortality rates. Therefore, targeting the NFκB pathway shows promise in cancer therapy. MATERIALS AND

methodsThis study investigated the impact of two NFκB inhibitors, LY2409881 and MLN4924, on cell proliferation, apoptosis susceptibility, and in vivo tumorigenesis in OSCC cell lines CAL27 and SCC15.

resultsThe results revealed that both LY2409881 and MLN4924 effectively suppressed cell proliferation, induced apoptosis, and arrested the cell cycle at the G2/M phase-a phenomenon likely associated with the NFκB pathway. Furthermore, MLN4924 demonstrated potent inhibitory effects on cell proliferation at low μM concentrations, surpassing the effectiveness of LY2409881 as an inhibitor (All results: p<0.05).

conclusionThese findings highlight the potential of LY2409881 and MLN4924 as novel therapeutic agents for OSCC, thereby offering new insights for the clinical management of this condition.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellCyclopentanesMouth NeoplasmsNF-kappa BPyrimidinesAnimalsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceStructure-Activity RelationshipAntineoplastic AgentsCyclopentanesNF-kappa BpevonedistatPyrimidinesinhibitorLY2409881MLN4924neddylation.NFκBOral squamous cell carcinoma (OSCC)

Identifiers

PMID39192651
PMCPMC12645110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.